Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Gemcitabine in Combination with Paclitaxel in the First-Line Treatment of Metastatic Breast Cancer

Gemcitabine in Combination with Paclitaxel in the First-Line Treatment of Metastatic Breast Cancer Am J Cancer 2005; 4 (5): 334-335 GUEST COMMENTARIES 1175-6357/05/0005-0334/$34.95/0 © 2005 Adis Data Information BV. All rights reserved. In the next few years we will be learning more about the use of Gemcitabine in Combination with Paclitaxel gemcitabine in breast cancer in terms of scheduling, combining it in the First-Line Treatment of Metastatic with other drugs, and adjuvant therapy. Breast Cancer The current use for gemcitabine in combination regimens is in a A Viewpoint by Ramon Colomer day 1, day 8 schedule. There is a lot of experience with weekly Department of Oncology, Catalan Institute of Oncology, administration of paclitaxel, and it is likely that a way will be found to include gemcitabine in a weekly schedule. Similarly, Girona, Spain several studies have highlighted the high efficacy and low toxicity of biweekly combinations of gemcitabine and paclitaxel. Gemcitabine has been a valuable alternative for patients with previously treated advanced breast cancer. Now, all major regula- In addition to paclitaxel, gemcitabine has been shown in several phase II breast cancer trials to combine very well with docetaxel, tory agencies around the world have also approved its use in vinorelbine, and also the monoclonal antibody trastuzumab. earlier stages, in combination http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Gemcitabine in Combination with Paclitaxel in the First-Line Treatment of Metastatic Breast Cancer

American Journal of Cancer , Volume 4 (5) – Aug 10, 2012

Gemcitabine in Combination with Paclitaxel in the First-Line Treatment of Metastatic Breast Cancer

Abstract

Am J Cancer 2005; 4 (5): 334-335 GUEST COMMENTARIES 1175-6357/05/0005-0334/$34.95/0 © 2005 Adis Data Information BV. All rights reserved. In the next few years we will be learning more about the use of Gemcitabine in Combination with Paclitaxel gemcitabine in breast cancer in terms of scheduling, combining it in the First-Line Treatment of Metastatic with other drugs, and adjuvant therapy. Breast Cancer The current use for gemcitabine in combination regimens is in a A Viewpoint by Ramon...
Loading next page...
 
/lp/springer-journals/gemcitabine-in-combination-with-paclitaxel-in-the-first-line-treatment-THQA0FAcP4
Publisher
Springer Journals
Copyright
Copyright © 2005 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200504050-00010
Publisher site
See Article on Publisher Site

Abstract

Am J Cancer 2005; 4 (5): 334-335 GUEST COMMENTARIES 1175-6357/05/0005-0334/$34.95/0 © 2005 Adis Data Information BV. All rights reserved. In the next few years we will be learning more about the use of Gemcitabine in Combination with Paclitaxel gemcitabine in breast cancer in terms of scheduling, combining it in the First-Line Treatment of Metastatic with other drugs, and adjuvant therapy. Breast Cancer The current use for gemcitabine in combination regimens is in a A Viewpoint by Ramon Colomer day 1, day 8 schedule. There is a lot of experience with weekly Department of Oncology, Catalan Institute of Oncology, administration of paclitaxel, and it is likely that a way will be found to include gemcitabine in a weekly schedule. Similarly, Girona, Spain several studies have highlighted the high efficacy and low toxicity of biweekly combinations of gemcitabine and paclitaxel. Gemcitabine has been a valuable alternative for patients with previously treated advanced breast cancer. Now, all major regula- In addition to paclitaxel, gemcitabine has been shown in several phase II breast cancer trials to combine very well with docetaxel, tory agencies around the world have also approved its use in vinorelbine, and also the monoclonal antibody trastuzumab. earlier stages, in combination

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

There are no references for this article.